U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H18FN3
Molecular Weight 282.3459
Optical Activity ( - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0
Stereo Comments RELATIVE

SHOW SMILES / InChI
Structure of XTRA F-18

SMILES

CN1[C@H]2CC[C@@H]1[C@H](C2)C3=CN=CC(=C3)C4=C([18F])N=CC=C4

InChI

InChIKey=ASRVLPPSPFUIAG-XOSDRLIHSA-N
InChI=1S/C17H18FN3/c1-21-13-4-5-16(21)15(8-13)12-7-11(9-19-10-12)14-3-2-6-20-17(14)18/h2-3,6-7,9-10,13,15-16H,4-5,8H2,1H3/t13-,15+,16+/m0/s1/i18-1

HIDE SMILES / InChI

Molecular Formula C17H18FN3
Molecular Weight 282.3459
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:53:11 GMT 2023
Edited
by admin
on Sat Dec 16 11:53:11 GMT 2023
Record UNII
03K6PV11JY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
XTRA F-18
Code English
(18F)XTRA
Common Name English
(-)-7-METHYL-2-EXO-(3-(2-(FLUORO-18F)-PYRIDIN-3-YL)-5-PYRIDINYL)-7-AZABICYCLO(2.2.1)HEPTANE
Systematic Name English
(1S,3R,4R)-3-(5-(2-(18F)FLUORANYL-3-PYRIDYL)-3-PYRIDYL)-7-METHYL-7-AZABICYCLO(2.2.1)HEPTANE
Systematic Name English
Code System Code Type Description
FDA UNII
03K6PV11JY
Created by admin on Sat Dec 16 11:53:11 GMT 2023 , Edited by admin on Sat Dec 16 11:53:11 GMT 2023
PRIMARY
PUBCHEM
145722025
Created by admin on Sat Dec 16 11:53:11 GMT 2023 , Edited by admin on Sat Dec 16 11:53:11 GMT 2023
PRIMARY
CAS
1044503-85-6
Created by admin on Sat Dec 16 11:53:11 GMT 2023 , Edited by admin on Sat Dec 16 11:53:11 GMT 2023
PRIMARY
Related Record Type Details
TARGET->RADIOLIGAND
NON-LABELED -> LABELED
Related Record Type Details
ACTIVE MOIETY
Recently, we discovered that XTRA (1) and AZAN (2) exhibited exceptionally high affinity and selectivity at .ALPHA.4.BETA.2-nAChRs.10 and 11 Pharmacological studies showed that they are .ALPHA.4.BETA.2-nAChRs antagonists with low side effects in mice. Their corresponding radioligands (18F)XTRA ((18F)1) and (18F)AZAN ((18F)2)10 and 11 were found to be excellent positron emission tomography (PET) radioligands in baboon. Their optimal imaging properties make them attractive candidates for further PET studies in human subjects. (18F)XTRA ((18F)1) and (18F)AZAN ((18F)2) were prepared from their corresponding bromo analogs, 3 and 4 and (18F) fluoride ion.